Abstract:Background & aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers remains poorly characterized. We compared the characteristics, management, survival, and trends of MASLD-related HCC in patients with or without underlying cirrhosis in a large multicenter cohort. Methods: A total of 354 cases of MASLD-related HCC presented at the liver tumor meetings of four French university hospitals between 2007 and 2018 were included in the study. Data were extracted from the meetings' databases and from the French Birth and Death Registry. Results: Of HCC cases, 35% occurred in the absence of cirrhosis. HCC was diagnosed through screening in 60% of patients with cirrhosis, and incidentally in 72% of patients without it. Patients without cirrhosis were older, had a greater tumor burden, but also better liver function than patients with cirrhosis. Patients without cirrhosis showed better overall survival than those with cirrhosis (p = 0.043). However, cirrhosis was not independently associated with overall survival, the independent predictors were age, liver function, tumor burden and BCLC classification. Patients without cirrhosis underwent surgery more frequently than patients with cirrhosis (41% vs. 11%, p <0.001), even in cases where the largest tumors were ≥5 cm (42% vs. 14%, p = 0.002) or there were four or more lesions (19% vs. 2%, p = 0.024). Among the patients (with/without cirrhosis) who underwent surgery, survival was not significantly different. The cirrhosis/no cirrhosis ratio remained stable over the study period. Conclusions: In MASLD-related HCC, patients without cirrhosis account for 35% of cases and have poor prognostic factors (higher age and larger tumors) but also better liver function, resulting in more aggressive management of advanced tumors and better survival compared to patients with cirrhosis. Impact and implications: The incidence of hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase by 47% to 130% by year 2030 with one-third of cases occurring in non-cirrhotic livers, making them inaccessible to screening and therefore more likely to be diagnosed at an advanced stage. Our study shows that survival in patients with MASLD-related HCC depends on age, tumor burden and underlying liver function and the preserved liver function of these non-cirrhotic patients allows them to be managed surgically. A better understanding of the pathophysiological processes driving HCC occurrence in patients with non-cirrhotic MASLD will help guide the screening and early management of these patients.

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study

Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care

Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up

Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis

Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease

Lower hepatocellular carcinoma surveillance in metabolic dysfunction‐associated steatotic liver disease: Impact on treatment eligibility

Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis

Metabolic‐associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Sub-Classification

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017-2018 cycle

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population

Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics

Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B

Current Concepts and Future Challenges

FIB-4 and Severe Liver Disease Outcomes in Primary Care: A Stratified Cox Analysis

The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD

From NAFLD to MASLD: when Metabolic Comorbidity Matters.

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection

FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease